Millennium Pharmaceuticals Limited

Kyowa Hakko Kirin Co., Limited

Otsuka Pharmaceutical Company, Limited

Kyowa Hakko Kogyo Co., Ltd.

Galenea Pharmaceuticals

Amy M Elder

Shomir Ghosh

Kenneth Gordon Carson

Jay R Luly

Yoshisuke Nakasato

Francois Soucy

Etsuo Ohshima

Geraldine C B Harriman

Karen M Mattia

Dominic J Reynolds

Kevin Sprott

Geraldine C Harriman

Tricia J Vos

Gang Li

Indu T Bharathan

Matthew O Duffey

Sean J Harrison

Jianping Guo

Kazumi Kondo

Masaki Suzuki

Akira Takahashi

Shin Miyamura

Takeshi Kuroda

Muneaki Kurimura

Prakash Raman

Satoshi Shimizu

Kevin J Hodgetts

Haruka Takahashi

Jason S Newcom

Tae Fukushima

Christelle C Renou

Qing Ye

Indranath Ghosh

Abhishek Dogra

Sian Griffiths

Krishna Reddy Valluru

Howard Paul Sard

Silvana Leit

Frederick A Hicks

Jeremy D Little

Doug Wilson

Yiliang Zhang

Jie Li

Geraldine CB Harriman

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Chemokine receptor antagonists and methods of use

Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP), such as those of formula (III), and composition thereof are described herein. Exemplary disorders include schizophrenia and cognitive deficit. 

Therapeutic compounds and related methods of use

Compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat a disorder, e.g., schizophrenia and cognitive deficit, in a subject are described herein. The compounds disclosed herein include quinoline and quinazoline-containing compounds that modulate striatal-enriched tyrosine phosphatase (STEP) activity.

Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

Compounds and methods of use thereof

Chemokine receptor antagonists and methods of use thereof

This invention provides compounds of formula I: 

Thiolactams and uses thereof

The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and Rare defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions. 

Compounds useful as antagonists of CCR2

The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions. 

Chemokine receptor antagonists and methods of use therefor

Disclosed are CRTH2 inhibitors represented by Structural Formula (I): The values for the variables of Structural Formula (I) are provided herein.

PGD2 receptor antagonists for the treatment of inflammatory diseases

Disclosed herein are compounds represented by Structural Formula (I) and (I-A):  Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof 

Growing community of inventors

Arlington, MA, United States of America

Amy M Elder